Core Viewpoint - Xianle Health reported a strong performance in Q3 2025, with significant year-on-year growth in both revenue and net profit [1] Financial Performance - The company achieved a revenue of 1,249,554,970.73 yuan in Q3 2025, representing a year-on-year increase of 18.11% [1] - The net profit attributable to shareholders of the listed company was 99,150,153.03 yuan, reflecting a year-on-year growth of 16.20% [1]

Core Insights - Xianle Health reported a revenue of approximately 3.291 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.96%, with a net profit of about 260 million yuan, up 8.53% year-on-year [1] - In Q3 2025, the company achieved a revenue of 1.250 billion yuan, marking an 18.11% increase year-on-year, and a net profit of 99 million yuan, which is a 16.20% growth year-on-year [1] - The company's growth is attributed to its adaptation to new consumer trends, international market expansion, and innovation-driven strategies [1] Revenue Growth - In Q3 2025, revenue and order volume in the China region grew by over 20% and 25% year-on-year, respectively, with new consumer clients accounting for more than half of the revenue in this region [1] - The revenue from MCN and private domain clients in Q3 increased by over 60% year-on-year, becoming the main growth engine for the company in China [1] - Mainstream product categories and dosage forms saw revenue growth of 60% and 50%, respectively, driven by a focus on younger and female consumer demographics [1] Client Development and International Expansion - Despite challenges faced by some traditional clients, the company maintains a strategy focused on developing key accounts, with revenue from strategic key accounts growing nearly 30% year-on-year in Q3 [2] - The company’s overseas business experienced growth in Q3 despite a complex trade environment, with exports to the Americas increasing by over 20% year-on-year [2] - The European market showed strong performance, with revenue growth of over 35% year-on-year in Q3, aided by partnerships with well-known health food retailers [2] Innovation and Technology Integration - The company is advancing its AI and R&D integration by signing a strategic cooperation agreement with Memory Tensor Technology to develop an AI formula engine [3] - The establishment of a smart logistics center in Shantou has increased storage capacity by approximately three times, enhancing inbound efficiency by about 70% [3] - The company is accelerating the construction of "dark factories" to create a standardized and replicable intelligent manufacturing system, aimed at reducing operational costs and enhancing supply chain collaboration [3]

Core Viewpoint - Xianle Health reported strong financial performance for Q3 2025, with significant year-on-year growth in both revenue and net profit [1] Financial Performance - In Q3 2025, the company achieved revenue of 1.25 billion yuan, representing a year-on-year increase of 18.11% [1] - The net profit attributable to shareholders for Q3 2025 was 99.15 million yuan, showing a year-on-year growth of 16.2% [1] - For the first three quarters of 2025, the company reported total revenue of 3.291 billion yuan, which is a year-on-year increase of 7.96% [1] - The net profit attributable to shareholders for the first three quarters of 2025 was 260 million yuan, reflecting a year-on-year growth of 8.53% [1]

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-099 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于举行 2025 年第三季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日 披露了《2025 年第三季度报告》。为便于广大投资者更深入、全面地了解公司情 况，公司定于 2025 年 11 月 3 日（星期一）下午 15:30 至 17:30 在全景网举办 2025 年第三季度业绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可 登陆"全景•路演天下"（http://rs.p5w.net）参与本次业绩说明会。 2 （问题征集专题页面二维码，扫码自动匹配移动端） 1 欢迎广大投资者积极参与。 仙乐健康科技股份有限公司 董事会 二〇二五年十月二十九日 出席本次 2025 年第三季度业绩说明会的人员有：公司董事长兼总经理林培 青先生，副总经理、 ...

仙乐健康科技股份有限公司 | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-097 | | --- | --- | --- | | 证券代码：123113 | 证券简称：仙乐转债 | | 特此公告。 仙乐健康科技股份有限公司 董事会 二〇二五年十月二十九日 1 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"）董事会于 2025 年 10 月 27 日召开第四届董事会第十五次会议，会议审议通过了公司《2025 年第三季度 报告》。 为使投资者全面了解公司 2025 年第三季度的经营成果和财务状况，公司 《2025 年第三季度报告》于 2025 年 10 月 29 日在中国证监会指定的创业板信息 披露网站上披露，敬请投资者注意查阅。 ...

二、董事会会议审议情况 经与会董事认真审议，本次会议以回收表决票的表决方式逐项表决通过了以 下决议： | 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-096 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 第四届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 仙乐健康科技股份有限公司（以下简称"公司"）第四届董事会第十五次会 议于 2025 年 10 月 27 日以通讯会议方式召开。会议通知于 2025 年 10 月 24 日以 电子邮件、微信信息等方式送达给全体董事及其他列席人员。本次会议由董事长 林培青先生召集和主持，应出席董事 8 人，实际出席董事 8 人。公司高级管理人 员列席本次会议。本次会议的召集、召开符合《中华人民共和国公司法》《中华 人民共和国证券法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》《仙乐健康科技股 份有 ...

Core Viewpoint - Xianle Health (300791.SZ) reported a revenue of 3.291 billion yuan for the first three quarters of 2025, reflecting a year-on-year growth of 7.96% [1] - The net profit attributable to shareholders of the listed company reached 260 million yuan, an increase of 8.53% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 244 million yuan, showing a year-on-year growth of 3.42% [1] - The basic earnings per share stood at 0.8523 yuan [1]

Core Insights - The company reported a revenue of 3.291 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 7.96% [1] - The net profit attributable to shareholders of the listed company was 260 million yuan, an increase of 8.53% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 244 million yuan, reflecting a year-on-year growth of 3.42% [1] - The basic earnings per share were 0.8523 yuan [1]

Core Insights - The company reported a third-quarter revenue of 1.25 billion yuan, representing a year-on-year growth of 18.11% [1] - The net profit for the third quarter was 99.15 million yuan, showing a year-on-year increase of 16.20% [1] - For the first three quarters, the total revenue reached 3.291 billion yuan, with a year-on-year growth of 7.96% [1] - The net profit for the first three quarters was 260 million yuan, reflecting a year-on-year increase of 8.53% [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥1,249,554,970.73, representing an 18.11% increase compared to the same period last year[5]. - Net profit attributable to shareholders was ¥99,150,153.03, up 16.20% year-on-year[5]. - The net profit excluding non-recurring gains and losses was ¥84,957,690.14, reflecting a 3.75% increase from the previous year[5]. - The basic earnings per share for the period was ¥0.4227, an increase of 16.25% compared to the same period last year[5]. - Total revenue for the current period reached ¥3,291,173,866.65, an increase of 7.96% compared to ¥3,048,456,382.86 in the previous period[38]. - The net profit for the current period is 221,833,210.02, an increase from 212,725,237.99 in the previous period, reflecting a growth of approximately 5.2%[40]. - The total comprehensive income for the current period is 250,123,513.03, compared to 203,533,929.20 in the previous period, indicating an increase of about 22.8%[40]. - The operating profit for the current period is 260,798,947.13, slightly up from 246,930,167.25 in the previous period, showing a growth of around 5.6%[40]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥5,877,959,247.31, a 7.14% increase from the end of the previous year[5]. - Total assets amounted to ¥5,877,959,247.31, an increase from ¥5,486,023,079.85, reflecting a growth of 7.13%[37]. - Total liabilities rose to ¥3,128,278,627.72, compared to ¥2,844,825,104.64 in the previous period, marking an increase of 9.96%[37]. - The company's equity attributable to shareholders increased to ¥2,654,056,548.87 from ¥2,505,833,682.05, a growth of 5.91%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥411,096,753.33, showing a significant increase of 45.50%[5]. - Cash flow from operating activities generated a net amount of 411,096,753.33, compared to 282,534,948.04 in the previous period, representing an increase of approximately 45.5%[41]. - The net cash flow from investing activities was negative at ¥294,337,407.24, a 136.64% increase in outflows compared to the previous year, mainly due to increased payments for long-term asset acquisitions[9]. - The net cash flow from investing activities is -294,337,407.24, worsening from -124,381,409.85 in the previous period, indicating a decline in investment cash flow[42]. - The net cash flow from financing activities is -214,036,504.12, compared to -125,820,210.74 in the previous period, showing a decrease in financing cash flow[42]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,761[11]. - Guangdong Guanghui Investment Co., Ltd. holds 42.76% of shares, totaling 131,414,400 shares[11]. - Lin Peiqing and Chen Qiong, as actual controllers, hold 9.12% and 5.56% of shares respectively, totaling 28,035,072 and 17,083,872 shares[11]. - The total number of restricted shares at the beginning of the period was 41,496,504, with 10,420,123 shares added during the period[15]. - The number of restricted shares held by Lin Peiqing increased to 21,026,304 after adding 4,852,224 shares[15]. - The company has a total of 50,794,063 restricted shares at the end of the period[15]. - The number of shares held by the top ten unrestricted shareholders includes 131,414,400 shares from Guangdong Guanghui Investment Co., Ltd.[12]. - The company has no changes in the top ten shareholders participating in margin trading[13]. - The company has no preferred shareholders or changes in preferred shareholders during the reporting period[14]. Stock Incentive and Repurchase - The company’s stock incentive plan includes 1,593,800 shares added to the restricted stock plan for 2025[16]. - The company completed the repurchase and cancellation of restricted stocks that were granted but not yet released from restrictions, amounting to 30% of the granted shares due to unmet release conditions[17]. - Company executives plan to reduce their holdings, with Vice General Manager Yao Zhuangmin intending to sell up to 2,019,489 shares (approximately 0.66% of total shares) and Director Yang Rui planning to sell up to 2,481,491 shares (approximately 0.81% of total shares)[18]. - Vice General Manager Zheng Liqun purchased 140,000 shares, representing 0.05% of the total share capital after excluding repurchased shares[19]. - Shareholder Yao Zhuangmin released 1,885,000 shares from pledge, leaving 715,000 shares still pledged[20]. - The company's registered capital increased from CNY 235,872,880 to CNY 307,318,960, and total shares increased from 235,872,880 to 307,318,960 due to the implementation of the 2025 restricted stock incentive plan and other adjustments[22]. - The company adjusted the repurchase price of the 2023 restricted stock incentive plan from CNY 9.78 per share to CNY 7.52 per share, and the number of shares involved was increased from 841,750 to 1,094,275[25]. Investments and Business Strategy - The company is investing up to USD 40 million to establish a production base in Thailand, with land acquisition costs approximately THB 489,285,000 (around CNY 108,626,162.85)[30]. - The company is seeking investment, divestment, or sale opportunities for its subsidiary Best Formulations PC LLC to optimize its U.S. business structure[31]. - The company approved the grant of 364,000 shares of restricted stock at a price of CNY 9.71 per share to 23 eligible participants under the 2025 restricted stock incentive plan[33]. - The company terminated the "Long-term Employee Stock Ownership Plan" due to significant changes in the market environment and the company's specific situation, which made the plan no longer suitable for current conditions[34]. Operating Costs and Expenses - Total operating costs increased to ¥3,046,438,602.78, up 8.26% from ¥2,813,726,698.28 in the previous period[38]. - Research and development expenses for the current period were ¥100,513,939.25, slightly up from ¥98,626,917.14 in the previous period[38]. - The company's cash and cash equivalents decreased to ¥541,548,259.12 from ¥636,030,607.22, a decline of 14.89%[35]. - Accounts receivable increased to ¥829,378,623.81, up 22.83% from ¥675,014,555.79 in the previous period[35]. - The company recorded a tax expense of 33,122,608.71 for the current period, compared to 29,224,869.86 in the previous period, which is an increase of approximately 13.3%[40].